This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Cramer's Action Alerts PLUS - See his portfolio and get alerts BEFORE every trade. Learn more NOW!

Myriad Genetics' MyPlan(TM) Lung Cancer Test Meets Primary Clinical Endpoint

SALT LAKE CITY, Sept. 25, 2013 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today announced new data published in Clinical Cancer Research that showed the myPlan Lung Cancer test is a significant predictor of lung cancer death in patients with early-stage, resectable lung adenocarcinoma and may be a valuable tool for selecting which early-stage patients should be considered for additional post-surgical chemotherapy.

"Lung cancer remains one of the most difficult-to-treat cancers. New prognostic markers to guide treatment decisions in early-stage, non-small cell lung cancer are necessary to improve outcomes for patients," said Edward S. Kim, M.D., co-author and chair of the Department of Solid Tumor Oncology and Investigational Therapeutics, Levine Cancer Institute, Carolinas HealthCare System, Charlotte NC. "In this verification study, the 31-gene cell cycle progression score was demonstrated to be a significant prognostic marker in resectable lung adenocarcinoma in that it stratifies patients' risk more effectively than conventional clinical parameters. This new information will further improve our ability to define the most appropriate treatment plan for surgically-treated, lung-cancer patients."

The purpose of this study was to investigate the significance of the myPlan Lung Cancer test as a predictor of survival in patients with early-stage lung adenocarcinoma in three independent data sets. The primary endpoint was overall survival as measured by disease related death within five years of surgery. Additionally, the study assessed the prognostic value of the score as compared to the conventional clinical variables of disease progression including age, stage of disease, gender, smoking status and tumor size. 

The myPlan Lung Cancer test measured mRNA expression levels of 31 cell cycle proliferation genes and 15 housekeeping genes in stage I and II tumor samples from a total of 841 patients. The results showed that myPlan Lung Cancer consistently was the strongest independent predictor of 5-year disease survival and remained the dominant prognostic marker in the presence of conventional clinical variables. 

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 18,214.42 -10.15 -0.06%
S&P 500 2,110.74 -3.12 -0.15%
NASDAQ 4,987.89 +20.7530 0.42%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs